LM-061

N/A

Report date: 2024/01/23 20:00:33
NME

Base Information

Drug NameLM-061
Drug Alias NameLM-061
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionHepatocyte growth factor receptor inhibitorsVascular endothelial growth factor receptor 2 inhibitorsTyrosine-protein kinase receptor FLT3 inhibitors
TargetsHepatocyte growth factor receptorVascular endothelial growth factor receptor 2Tyrosine-protein kinase receptor FLT3
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryAustraliaMainland China
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaDiscontinued
Originator CompaniesShanghai Lixin Pharmaceutical Research and Development Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesN/A
Inactive CompaniesLaNova Medicines LtdShanghai Lixin Pharmaceutical Research and Development Co Ltd
Active IndicationsN/A
Inactive IndicationsSolid tumours

Other Information

ATC CodeN/A
Related LinksN/A